CN104910159A - 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法 - Google Patents

纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法 Download PDF

Info

Publication number
CN104910159A
CN104910159A CN201510243421.1A CN201510243421A CN104910159A CN 104910159 A CN104910159 A CN 104910159A CN 201510243421 A CN201510243421 A CN 201510243421A CN 104910159 A CN104910159 A CN 104910159A
Authority
CN
China
Prior art keywords
pyrrolo
dihydro
trans
indol
quinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510243421.1A
Other languages
English (en)
Chinese (zh)
Inventor
D.P.里德
N.R.巴恩斯
J.C.凯恩
C.A.李
J.陈
M.P.雷蒙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arqule Inc
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of CN104910159A publication Critical patent/CN104910159A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201510243421.1A 2009-12-23 2010-12-21 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法 Pending CN104910159A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28956309P 2009-12-23 2009-12-23
US61/289563 2009-12-23
CN201080064457.9A CN102834097B (zh) 2009-12-23 2010-12-21 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201080064457.9A Division CN102834097B (zh) 2009-12-23 2010-12-21 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法

Publications (1)

Publication Number Publication Date
CN104910159A true CN104910159A (zh) 2015-09-16

Family

ID=44188284

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510243421.1A Pending CN104910159A (zh) 2009-12-23 2010-12-21 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法
CN201080064457.9A Active CN102834097B (zh) 2009-12-23 2010-12-21 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201080064457.9A Active CN102834097B (zh) 2009-12-23 2010-12-21 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法

Country Status (19)

Country Link
US (3) US8552192B2 (https=)
EP (2) EP2515904A4 (https=)
JP (2) JP2013515737A (https=)
KR (2) KR20160121602A (https=)
CN (2) CN104910159A (https=)
AU (2) AU2010336533B9 (https=)
BR (1) BR112012015656A2 (https=)
CA (1) CA2785503A1 (https=)
CO (1) CO6561823A2 (https=)
HK (1) HK1215025A1 (https=)
MX (1) MX2012007259A (https=)
MY (2) MY156701A (https=)
NZ (2) NZ628087A (https=)
PH (2) PH12012501293A1 (https=)
RU (1) RU2556205C2 (https=)
SG (1) SG181927A1 (https=)
TW (3) TWI506026B (https=)
WO (1) WO2011079142A2 (https=)
ZA (1) ZA201204759B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100941205B1 (ko) * 2005-02-09 2010-02-10 아르퀼 인코포레이티드 말레이미드 유도체, 약제학적 조성물 및 암을 치료하는방법
MY156701A (en) * 2009-12-23 2016-03-15 Arqule Inc Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
TW201315470A (zh) * 2011-07-07 2013-04-16 Arqule Inc 吡咯並喹啉基－吡咯啶－２，５－二酮調製劑類及製備和使用彼等之方法
WO2013162714A1 (en) * 2012-04-23 2013-10-31 Arqule, Inc. Highly pure pyrroloquinolinyl-pyrrole-2,5-dione and pyrroloquinolinyl-pyrrolidine-2,5-dione and methods of preparing same
EP3021849B1 (en) * 2013-07-16 2019-10-09 Dr. Reddy's Laboratories Ltd. Novel crystalline forms of pemetrexed tromethamine salts
CN111247153B (zh) * 2017-08-11 2024-04-02 开动疗法公司 3-(5-氟苯并呋喃-3-基)-4-(5-甲基-5H-[1，3]间二氧杂环戊烯并[4，5-f]吲哚-7-基)吡咯-2，5-二酮的固体形式
CN110806454A (zh) * 2018-08-06 2020-02-18 江苏正大清江制药有限公司 一种盐酸吉西他滨中手性异构体的检测方法
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022216870A1 (en) * 2021-04-07 2022-10-13 Ur-1 Therapeutics, Inc. Urat1 inhibitor, pharmaceutical compositions and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE4128015A1 (de) * 1991-08-23 1993-02-25 Kali Chemie Pharma Gmbh 1,7-anellierte 2-(piperazinoalkyl)indol-derivate sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindugnen enthaltende arzneimittel
US5760237A (en) * 1995-08-25 1998-06-02 California Institute Of Technology Synthesis of l-azatyrosine using pseudoephedrine as a chiral auxiliary
EP1242420A2 (en) * 1999-12-16 2002-09-25 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
ATE315017T1 (de) * 2002-07-31 2006-02-15 Firmenich & Cie Verfahren zur racematspaltung einer sclareolid- vorstufe
CA2573508A1 (en) * 2004-09-10 2006-03-23 Wyeth Process for the scalable synthesis of 1, 3, 4, 9-tetrahydropyrano[3, 4-b]-indole derivatives
KR100941205B1 (ko) * 2005-02-09 2010-02-10 아르퀼 인코포레이티드 말레이미드 유도체, 약제학적 조성물 및 암을 치료하는방법
US20070185346A1 (en) * 2006-02-03 2007-08-09 Vaidya Niteen A Kit for automated resolving agent selection and method thereof
EP2170870B1 (en) 2007-06-22 2014-03-05 ArQule, Inc. Pyrrolidinone, pyrrolidine-2, 5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
CA2912546A1 (en) * 2007-06-22 2008-12-31 Arqule, Inc. Compositions and methods for treatment of cancer
MY156701A (en) * 2009-12-23 2016-03-15 Arqule Inc Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
WO2013162714A1 (en) * 2012-04-23 2013-10-31 Arqule, Inc. Highly pure pyrroloquinolinyl-pyrrole-2,5-dione and pyrroloquinolinyl-pyrrolidine-2,5-dione and methods of preparing same

Also Published As

Publication number Publication date
AU2015243015A1 (en) 2015-11-05
MX2012007259A (es) 2015-05-15
EP3081567A2 (en) 2016-10-19
KR101669707B1 (ko) 2016-10-27
US20140031551A1 (en) 2014-01-30
EP2515904A4 (en) 2013-07-03
TWI557125B (zh) 2016-11-11
KR20120113760A (ko) 2012-10-15
CA2785503A1 (en) 2011-06-30
CN102834097A (zh) 2012-12-19
PH12014500310A1 (en) 2015-09-28
NZ628087A (en) 2016-02-26
US8552192B2 (en) 2013-10-08
HK1215025A1 (zh) 2016-08-12
WO2011079142A2 (en) 2011-06-30
AU2010336533B2 (en) 2015-09-10
TW201542546A (zh) 2015-11-16
AU2015243015B2 (en) 2017-02-02
EP3081567A3 (en) 2016-11-16
SG181927A1 (en) 2012-07-30
BR112012015656A2 (pt) 2016-05-10
US9499540B2 (en) 2016-11-22
RU2012131344A (ru) 2014-01-27
RU2556205C2 (ru) 2015-07-10
NZ600800A (en) 2014-10-31
JP2013515737A (ja) 2013-05-09
US20110160242A1 (en) 2011-06-30
WO2011079142A3 (en) 2011-11-24
EP2515904A2 (en) 2012-10-31
US20160024076A1 (en) 2016-01-28
CN102834097B (zh) 2015-06-17
CO6561823A2 (es) 2012-11-15
MY169232A (en) 2019-03-19
AU2010336533A1 (en) 2012-07-12
KR20160121602A (ko) 2016-10-19
TW201643163A (zh) 2016-12-16
TW201141865A (en) 2011-12-01
TWI506026B (zh) 2015-11-01
MY156701A (en) 2016-03-15
ZA201204759B (en) 2014-03-26
US8871933B2 (en) 2014-10-28
AU2010336533B9 (en) 2015-10-08
JP2016041712A (ja) 2016-03-31
PH12012501293A1 (en) 2013-01-07

Similar Documents

Publication Publication Date Title
CN102834097B (zh) 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法
CN103282365B (zh) 结晶的(8S,9R)‑5‑氟‑8‑(4‑氟苯基)‑9‑(1‑甲基‑1H‑1,2,4‑三唑‑5‑基)‑8,9‑二氢‑2H‑吡啶并[4,3,2‑de]酞嗪‑3(7H)‑酮甲苯磺酸盐
CN107074769B (zh) 用于治疗增生性病症的组合物和方法
EP3683220A1 (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of huntigton's disease
TR201807101T4 (tr) İmidazo[4,5-c]kinolin-2-on bileşikler ve kanserin tedavi edilmesinde kullanımları.
CN101133055A (zh) 用于治疗癌症的meleimide衍生物、药物组合物以及方法
EP4353724A1 (en) Compound as cdk kinase inhibitor and use thereof
KR20180067531A (ko) Pim 카이나제 저해제의 염
JP2021504332A (ja) ピラゾロピリジノン化合物
US8343977B2 (en) Substituted triazolo-pyrimidine compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1215025

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150916

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1215025

Country of ref document: HK